Want to join the conversation?
$MMSI said it received notification of substantial equivalence from the FDA for the Corvocet Biopsy System, intended for use in obtaining core biopsy samples from the liver, kidney, prostate, breast, lung and various other soft tissue tissue tumors. Corvocet is scheduled to be introduced in the US over the next 30 days or so.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.